SYRE insider trading
HealthcareSpyre Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Spyre Therapeutics, Inc.
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.
Company website: www.spyre.com
SYRE insider activity at a glance
FilingIQ has scored 60 insider transactions for SYRE since Nov 24, 2023. The most recent filing in our index is dated May 8, 2026.
Across the full history, 0 open-market purchases
and 37 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on SYRE insider trades is 65.8/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest SYRE Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
13F funds holding SYRE
Frequently asked
- How many insider trades does FilingIQ track for SYRE?
- FilingIQ tracks 60 Form 4 insider transactions for SYRE (Spyre Therapeutics, Inc.), covering filings from Nov 24, 2023 onwards. 37 of those were filed in the last 90 days.
- Are SYRE insiders net buyers or net sellers?
- Across the full Form 4 history for SYRE, 0 transactions (0%) were open-market purchases and 37 (62%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does SYRE insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is SYRE in?
- Spyre Therapeutics, Inc. (SYRE) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $2.74B.
Methodology & sources
Every SYRE insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.